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Abstract
Hydroxychloroquine is a highly effective and commonly used disease-modifying anti-rheumatic
drug (DMRD) for the treatment of various autoimmune diseases. Recently this medication
received lot of attention in the medical world as a potential treatment for COVID-19. The goal of
this research is to perform a systematic review of literature to focus on the efficacy of
hydroxychloroquine in COVID-19 patients and any evidence of adverse reactions. The database
used to conduct this research was PubMed, using four keywords and phrases: effects, side effects,
adverse events, and serious adverse events of hydroxychloroquine in COVID-19 patients. Out of
the 15 articles selected for the final review, 12 articles indicated no clinical improvement and 10
articles did not indicate any evidence of adverse reactions. The conclusion of the research is that
hydroxychloroquine indicates lack of efficacy as treatment in patients with COVID-19, and there
is not enough conclusive evidence for adverse reactions.
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Introduction
Hydroxychloroquine sulfate (also known as hydroxychloroquine and abbreviated as
HCQ) is an antimalarial medicine approved in 1956 by the U.S. Food and Drug Administration
(FDA, 2020a) for either prevention or treatment of certain types of malaria, lupus erythematosus,
and rheumatoid arthritis. This drug belongs to the drug class called antimalarial quinolines or
antirheumatics. It is a disease-modifying antirheumatic drug, also known as DMRD (Lupus
Foundation of America, 2020). Currently, it is used to treat rheumatoid arthritis, some symptoms
of lupus, childhood arthritis, and other autoimmune diseases (American College of
Rheumatology, 2020). This drug is proven to be highly effective in reducing pain, stiffness, and
inflammation associated with arthritis. It is believed that hydroxychloroquine interferes with the
communication of cells in the immune system (American College of Rheumatology, 2020).
Hydroxychloroquine comes as an oral tablet with adult dosing ranging from 200 mg to
400 mg per day for rheumatic diseases and it needs a prescription. It is recommended to be taken
with food. Symptoms can improve in one to two months, but it may take up to six months before
the full benefits of this medication are experienced (American College of Rheumatology, 2020).
Some of the common brand names of hydroxychloroquine are Plaquenil, Hydroquin, Axemal,
and Dolquine, but Plaquenil is the most common brand. Hydroxychloroquine is in the World
Health Organization's List of Essential Medicines (WHO, 2019), which shows the significance
of hydroxychloroquine for the treatment of common autoimmune diseases. Antimalarials have
been used to treat autoimmune diseases for years, and among them, hydroxychloroquine and
chloroquine are often first-choice therapies. The efficacy of antimalarials is related to a strong
modulation of the immune response as well as their photo protective properties (Rios-Fernandez,
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2019). Due to its cost-effectiveness, safety, and efficacy hydroxychloroquine is especially used
in rheumatic autoimmune disorders (RADs), such as rheumatoid arthritis, systemic lupus
erythematosus, and primary Sjogren’s syndrome (Nirk et al., 2020). The label for plaquenil,
which is one of the popular brand names of hydroxychloroquine, is presented in Figure 1.

Figure 1
Label of Plaquenil

Note. An example of the label of Hydroxychloroquine sulfate (Plaquenil) from Concordia
Pharmaceuticals Incorporation. Adapted from GNH India.com, 2021, Retrieved from
https://www.gnhindia.com/products/us-ndc/hydroxychloroquine-sulfate-plaquenil-59212-562/.
Copyright 2021 by GNH India.com.
In order to reiterate the significance of hydroxychloroquine for the treatment of
autoimmune diseases, four major autoimmune disease states are evaluated and analyzed in
comparison with most recent DMRDs. The four diseases chosen for this task are rheumatoid
arthritis, systemic lupus erythematosus (SLE), Sjogren’s syndrome, and porphyria cutanea tarda
(PCT).
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Rheumatoid Arthritis
Rheumatoid Arthritis is a common, chronic, and systemic inflammatory autoimmune
disease. The major treatments for rheumatoid arthritis currently are non-steroidal antiinflammatory drugs (NSAIDs), like aspirin and ibuprofen, and disease-modifying anti rheumatic
drugs (DMRDs), like methotrexate and hydroxychloroquine. The newest classes of medications
used to treat rheumatoid arthritis are called biological response modifiers, and they have been
available for almost 10 years now (Gaffo et al., 2006). Some of the major biological agents that
are used to treat RA are Infliximab, Adalimumab, and Etanercept (Gaffo et al., 2006). These
agents act as human tumor necrosis factor alpha (TNF-α) inhibitors are designed to target the
inflammatory mediators of tissue damage in rheumatoid arthritis (Gaffo et al., 2006). Even
though the biological agents indicated similar efficacy results as the DMRDs, the efficacy of
combination therapy is greater than monotherapy with either agent (Gaffo et al., 2006).
Combination of DMRD therapy is generally well tolerated and a reasonable alternative to more
expensive biological therapies (Gaffo et al., 2006). Even though there are several categories of
treatments available currently, using DMRDs as monotherapy and as combination therapy
depending on the severity of the disease is considered the first line treatment, and so
hydroxychloroquine holds a significant role in the treatment of rheumatoid arthritis.
Systemic Lupus Erythematosus (SLE)
Systemic lupus erythematosus is the most common type of lupus. It is an autoimmune
disease causing widespread inflammation and damage in the affected organs which
predominantly affects women of childbearing age (D’Cruz, 2007). As an FDA-approved firstline indication, many people use hydroxychloroquine as an effective treatment. Not only has
hydroxychloroquine been shown to prevent lupus flares, it also increases long-term survival of
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patients with systemic lupus erythematosus (Husayn et al., 2020). It exhibits protective effects
against lupus-associated organ damage, thrombosis, and bone density. In addition,
hydroxychloroquine is also safe to use during pregnancy and breastfeeding. From 2001 to 2015,
there was a rise in the proportion of women taking hydroxychloroquine during pregnancy due to
safety studies suggesting a population in need of this drug (Husayn et al., 2020). According to
the Lupus Foundation of America, no other drug provides similar broad benefits as
hydroxychloroquine (Husayn et al., 2020). Quinacrine may be an alternative for patients with
poor response or those who are intolerant to other antimalarials with the most frequent side effect
of yellow skin discoloration (Rios-Fernandez, 2019). Among possible treatments for SLE,
hydroxychloroquine comes as the first-line treatment because of its efficacy in treating
autoimmune diseases.
Sjogren’s Syndrome
Sjogren’s syndrome is a chronic and very common autoimmune disorder of the exocrine
glands with associated lymphocytic infiltrates of the affected glands (Fox, 2005). The dryness of
the eyes and mouth results from the involvement of the salivary and lacrimal glands (Fox, 2005).
The exocrinopathy can be encountered alone as primary Sjogren’s syndrome or in the presence
of another autoimmune disorder such as rheumatoid arthritis, systemic lupus erythematosus, or
progressive systemic sclerosis. (Fox, 2005). As treatment, the Sjogren’s Syndrome Foundation
(SSF) experts recommended a therapeutic step-by-step scheme that begins with
hydroxychloroquine, and if the response is insufficient, methotrexate is indicated in the next step
also in combination with hydroxychloroquine (Witte, 2019). If the first-line treatment is
unsuccessful, other treatments like leflunomide, sulfasalazine, or azathioprine could be
considered (Witte, 2019). Another reserve drug is cyclosporine, which can be used if the patient
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does not respond to the other drug (Witte, 2019). In conclusion, hydroxychloroquine and a
combination of hydroxychloroquine with methotrexate comes as the primary treatment for
Sjogren’s syndrome.
Porphyria Cutanea Tarda (PCT)
Porphyria cutanea tarda (PCT) is a disease of uroporphyrinogen decarboxylase inhibition,
an enzyme involved in heme synthesis which eventually causes skin blisters (Husayn et al.,
2020). Current treatment for PCT involves treatment with phlebotomy and hydroxychloroquine.
Phlebotomy removes large quantities of blood, which removes iron, a substrate involved in heme
synthesis. Hydroxychloroquine is an effective treatment strategy for PCT and may be superior to
phlebotomy (Husayn et al., 2020). Low, oral doses of hydroxychloroquine 100 mg by mouth
twice weekly reduces potential adverse effects while maintaining comparable safety and efficacy
to phlebotomy (Husayn et al., 2020). Considering patient compliance, cost, and convenience,
hydroxychloroquine is the reasonable option for patients with PCT (Husayn et al., 2020).
Based on the evaluation of above-mentioned disease states and the respective treatments,
it is evident that there are not many alternate drugs in the market that are proven to be more
effective and safer than hydroxychloroquine. Hydroxychloroquine is routinely prescribed to
children with systemic lupus, and the side-effect profile is expected to be the same as adults
(Chew, 2020). It is also advised that women with systemic lupus erythematosus or anti-Ro
antibody-positive cutaneous lupus continue hydroxychloroquine during pregnancy when it is
clinically indicated (Chew, 2020). All these facts indicate that hydroxychloroquine is well
tolerated in pediatric patients and even during pregnancy. There are certain choices available for
patients who cannot tolerate DMRDs, but hydroxychloroquine is considered as the primary
treatment for many of the autoimmune disorders with proven safety and efficacy.
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Background
The research involving hydroxychloroquine is highly significant at this point because of
the recent use of this drug as a potential treatment for COVID-19. In March 2020, the FDA
approved the Emergency Use Authorization (EUA) to use hydroxychloroquine to treat COVID19 (FDA, 2020b). In June 2020, the FDA revoked the Emergency Use Authorization because it
was determined that hydroxychloroquine is not an effective treatment for COVID-19 (FDA,
2020a). Millions of people took this drug during early 2020 as potential treatment for COVID-19
and resulted in a world-wide demand and shortage of supply. The subject for this research is so
relevant at the time of this global pandemic since approval of hydroxychloroquine as potential
treatment for COVID-19 was not based on evidence. It is a classic example of practice changing
despite limited evidence to support its use. The use of hydroxychloroquine to treat COVID-19
patients was against the principles of evidence-based medicine. Evidence-based medicine (EBM)
is the conscientious, explicit, and judicious use of current best evidence in making decisions
about the care of individual patients (Sackett et.al, 1996). The use of hydroxychloroquine in the
face of the COVID-19 pandemic could be justified because both physicians and patients were
scared, overwhelmed, and wanted fast answers. Another justification to use hydroxychloroquine
as potential treatment for COVID-19 is that the traditional approach to validate a new treatment
takes a long time.
The short-term and long-term side effects and adverse reactions caused by
hydroxychloroquine in COVID-19 patients is still under evaluation and remains mostly unclear.
Having an understanding on the reported adverse reactions of hydroxychloroquine in the current
labeling will be beneficial prior to focusing on the adverse reactions caused by this drug in
COVID-19 patients. As it was mentioned in the introduction, hydroxychloroquine is a commonly
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used drug to treat many autoimmune diseases. The current labeling of hydroxychloroquine
indicates a wide array of adverse reactions. Adverse drug reactions (ADR) are a major burden for
patients, drug manufacturers and the healthcare industry because it is highly unpredictable. Early
and accurate detection of potential ADRs can help to drug safety and reduce financial costs (Liu,
2019). Post-market spontaneous reports of ADRs remain a cornerstone for pharmacovigilance
and a series of drug safety signal detection methods play an important role in providing drug
safety insights. (Liu, 2019). The adverse reactions of hydroxychloroquine listed in the current
labeling are presented in Table 1.
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Table 1
Reported Adverse Reactions in the Current Labeling of Plaquenil

Note. Reported Adverse Reactions Listed in the Current Labeling of Plaquenil,
Hydroxychloroquine sulfate tablets, U.S. Pharmacopeia. Adapted from FDA.gov, 2017,
Retrieved from
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf.
Copyright 2015 by Concordia Pharmaceuticals Incorporation.
The most common cutaneous adverse reaction associated with hydroxychloroquine
specified in the current labeling is skin pigmentation (Charfi et al., 2015). Acute generalized
exanthematous pustulosis (AGEP) is a severe cutaneous adverse induced by hydroxychloroquine
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(Charfi et al., 2015). There are only 26 cases of hydroxychloroquine induced AGEP that were
documented following a Medline search (Charfi et al., 2015). Based on Individual Case Safety
Reports (ICSR) registered in VigibaseR (1 January 2010 to 31 December 2019) according to
Standardised MedDRA Queries (SMQs) classification, the main ADRs associated with
hydroxychloroquine were hypersensitivity and allergic reactions, arthralgia, and skin disorders
(Montastruc et al., 2020). Drug rash with eosinophilia and systemic symptoms (DRSS), acute
generalized exanthematous pustulosis (AGEP), erythema multiforme, stevens-johnson syndrome,
and toxic epidermal necrolysis have been reported associated with hydroxychloroquine (Chew,
2020). Adequate warnings from the physicians at the time of prescription will alert patients
especially patients who take this treatment for the first time for any adverse reactions. It will
allow the patients to cease the medication in a timely manner to stop any potential allergic
reactions.
Another common adverse reaction in the current labeling is the well-known retinal
toxicity caused by hydroxychloroquine after long-term use. Retinopathy is any damage to the
retina of the eyes that can cause vision loss. Long-term treatment with hydroxychloroquine had
been reported to cause severe irreversible retinal toxicity in susceptible individuals. According to
Latasiewics (2017), hydroxychloroquine has now been shown to be associated with significant
retinal toxicity. According to the same article, older studies have estimated hydroxychloroquine
toxicity to be infrequent at around 0.5% to 1% of those taking hydroxychloroquine for greater
than 5 years. Recent epidemiological data indicate that retinal toxicity occurs in greater than 10%
of the patients who have taken hydroxychloroquine for over 10 years, and 20% to 50% of
patients taking hydroxychloroquine for more than 20 years (Latasiewics, 2017). Studies show
that retinal toxicity associated with hydroxychloroquine is an important problem with major
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human and economic consequences ranging from blindness to the cost of screening (Wolfe &
Marmor, 2010). Hydroxychloroquine retinopathy is of concern because of the potential
seriousness of visual loss and the medicolegal consequences of failure to detect toxicity (Wolfe
& Marmor, 2010). The risks associated with clinical parameters such as age, dose, cumulative
dose, and duration of use will provide the tools for clinical societies to improve screening
policies and guidelines and for individual physicians to make better judgement about the
management of the disorder (Wolfe & Marmor, 2010).
The most interesting results based on the Individual Case Safety Reports (ICSR) were the
relative high percent of cardiac ADRs (cardiomyopathy + arrhythmias = 8.3% of total ICSRs)
showing that hydroxychloroquine first possess a myocardial toxicity, and second, can disturb
cardiac rhythm (Montastruc et al., 2020). The fact that reported deaths were more than one out of
three times from cardiac origin agrees with this conclusion. The present results show that the
cardiac signal (QT prolongation and arrhythmias) found with hydroxychloroquine in COVID-19
patients were already present with rheumatoid arthritis and lupus (Montastruc et al., 2020).
There are several research studies indicating close association of hydroxychloroquine and
cardiac adverse events not only in COVID-19 patients but also in patients with autoimmune
disorders. According to Cohen et al. (2020), there was an increased reporting of cardiac adverse
events in FDA Adverse Event Reporting System (FAERS) and its older version known as
Adverse Event Reporting System (AERS) reports of chloroquine and hydroxychloroquine with
respect to other therapeutics used for RA and SLE. This particular study analyzed 702,274 each
of the FDA’s adverse event reports which divided into chloroquine, hydroxychloroquine and
control cohorts to determine their association with cardiac adverse events (Cohen et al., 2020).
This study is indicating the connection of cardiac adverse events caused by hydroxychloroquine.
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Based on the article “Cardiac Adverse Events Associated With Chloroquine and
Hydroxychloroquine Exposure in 20 Years of Drug Safety Surveillance Reports,” in addition to
the existing disease condition, other reasons like age, sex, and concurrent NSAID use were
identified to contribute to cardiotoxicity reporting with hydroxychloroquine (Cohen et al., 2020).
Hydroxychloroquine was used to treat COVID-19 based on pre-existing in-vitro evidence
of chloroquine and hydroxychloroquine reactions against viruses, specifically SARS-CoV2,
made it a plausible option for COVID-19 (Edelman et al., 2020). This drug was an attractive
choice for COVID-19 because not only did it show in-vitro evidence against the virus, but it also
was already approved for other indications with well-documented safety profile and post market
surveillance (Edelman et al., 2020). However due to accumulating data on the serious cardiac
adverse events, the FDA determined the potential benefits no longer outweighed the risks of the
medication. As it was mentioned earlier, on June 15, 2020, the FDA revoked the emergency use
authorization for hydroxychloroquine in COVID-19 patients as the required legal criteria was no
longer met.
Because of the increased number cardiac adverse events caused by this drug especially in
COVID-19 patients, it was in the list of FDA Adverse Event Reporting System (FAERS)
between April to June 2020, for further regulatory evaluation due to cardiotoxicity (FDA,
2020c). In critically ill COVID-19 patients, the risk of adverse cardiac events associated with the
use of chloroquine and hydroxychloroquine is significantly high because of the impact on the
myocardium due to cytokine storm from aggressive pulmonary infection and possible hypoxia in
addition to the potential for viral myocarditis (Kamp et al., 2020). As of September 28, 2020, the
status of hydroxychloroquine sulfate (plaquenil), chloroquine phosphate, and generic products
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containing hydroxychloroquine and chloroquine, are evaluated by the FDA for the need of any
regulatory action (FDA, 2020c).
Since hydroxychloroquine is still considered as a significant treatment for autoimmune
diseases, it is important to focus on the efficacy of this drug in COVID-19 patients, especially
when it was used on patients without data from clinical trials. The purpose of this research is to
conduct a systematic review of literature for evidence of efficacy of hydroxychloroquine in
COVID-19 patients based on results from clinical trials. In addition, the study will also focus on
any evidence of adverse reactions reported in patients as a result of using hydroxychloroquine as
treatment for COVID-19.
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Methods
The method that was used to conduct this research project was a systematic review of
literature based on clinical trials that focused on the efficacy of hydroxychloroquine in COVID19 patients. Systematic reviews and meta-analyses are being increasingly used to summarize
medical literature and identify areas in which research is needed (Crowther & Lim, 2010).
Systematic reviews limit bias with the use of reproducible scientific process to search the
literature and evaluate the quality of the individual studies, and if possible, results are statistically
combined into meta-analyses in which the data is weighted and pooled to produce an estimate of
effect (Crowther & Lim, 2010). A meta-analysis is a statistical study that combines the result of
several scientific studies on the topic. It is a quantitative, formal and epidemiological study
design used to systematically assess the results of previous research to drive conclusions about
the body of the research (Haidich, 2010). Outcomes from a meta-analysis may include a precise
estimate of the effect of treatment, or risk factor for disease, or other outcomes than any
individual study contributing to the pooled analysis (Haidich, 2010). Since the results gathered
for the purpose of writing this thesis is qualitative than quantitative, the meta-analyses part is not
that significant compared to systematic review.
As per Crowther and Lim (2010), the inferences made from systematic reviews are
usually evidence based. As it is indicated in Figure 2, the quality of evidence derives from
observational studies, experimental studies, and critical appraisal. The search for evidence is
mainly using electronic databases like PubMed, MEDLINE, Embase, and Cochrane Library. The
completeness of the search strategy will determine the comprehensiveness of the review
(Crowther & Lim, 2010). Apart from the above mentioned electronic databases, many other
sources like registers of clinical trials (www.clinicaltrials.gov), data clearing houses
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(www.guideline.gov) and agencies like FDA and CDC (www.FDA.gov and www.CDC.gov)
could be used for literature review.

Figure 2
Quality of Evidence Pyramid

Note. The Evidence Based Medicine Pyramid. Adapted from cochrane.org, by D. Minkow,
2014, Retrieved from https://s4be.cochrane.org/blog/2014/04/29/the-evidence-based-medicinepyramid/. Copyright 2021 by Students 4 Best Evidence.
For the purpose of conducting this research, the main source of literature review is
PubMed. The reason the search was limited to only one electronic database was to control the
enormous search results related to hydroxychloroquine because of the pandemic. Published
literature from sources other than PubMed and websites of agencies and foundations, especially
the U.S. Food and Drug Administration, were also used to gather evidence for this research. The
studies selected for the literature review were chosen from PubMed published between October
2020 and September 2021. The text-availability filter was selected for abstract, and the articletype filter was selected for clinical trial and randomized controlled trial. The publication date
selected was for one year. The summary for the search filters is given in table format in Table 2.
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Table 2
Search Filters Used in PubMed
PubMed.gov

Selected Filters

Text Availability

Abstract

Article Type

Clinical Trial and Randomized Controlled Trial

Publication Date

1 Year

The search on PubMed was conducted using four key words as effects, side effects,
adverse events and serious adverse events of hydroxychloroquine in COVID-19 patients. The
articles were evaluated based on the inclusion and exclusion criteria established and specified
below. The abstracts were reviewed for all articles and categorized based on the primary and
secondary outcome presented below. The elimination of studies was based on multiple reasons
such as duplicate, not relevant, no abstract available and not based on clinical trials. A PRISMA
flowchart is presented with details of the selection process is presented in Figure 3. The selected
studies were further categorized into type of study, primary outcome, and secondary outcome in
COVID-19 patients. A summary of all the selected studies is presented in the Appendix.
Inclusion Criteria
Studies satisfying the following criteria were included in the analysis:
● articles published within one year (between October 2020 and September 2021),
● samples which included COVID-19 patients,
● studies based on only clinical trials and randomized controlled trials, and
● abstracts that specifically addressed the primary and secondary outcomes for the search.
Exclusion Criteria
Any study that had one of the following criteria were excluded:
● articles published before October 2020,

16

● studies based on any other methods except clinical trial and randomized controlled
clinical trial,
● abstracts that did not address the primary and secondary outcome for the search,
● articles that did not directly address the issues of COVID-19 patients, and
● articles in any other languages other than English.
Primary Outcome
● Evidence for any clinical improvement of symptoms of COVID-19 patients by using
hydroxychloroquine.
Secondary Outcome
● Signs of adverse events caused specifically by hydroxychloroquine in COVID-19
patients.
● Signs of serious adverse events caused specifically by hydroxychloroquine in COVID-19
patients.
● Reported adverse events of hydroxychloroquine with any other combination drugs in
COVID-19 patients.
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Results
The results for the initial search are presented in a table format for each keyword (see
Table 3). The search results were further screened based on the inclusion and exclusion criteria,
and the results are presented in a flow chart format (see Figure 3). The articles selected for final
evaluation were based on the primary and secondary outcomes mentioned in the methods
section.

Table 3
Results of Keyword Search

Key Words

Number of Publications
(PubMed) October 2020September 2021

Effects of hydroxychloroquine in COVID-19 patients

44

Side Effects of hydroxychloroquine in COVID-19
patients

20

Adverse Events of hydroxychloroquine in COVID-19
patients

12

Serious Adverse of Events of hydroxychloroquine in
COVID-19 patients

5

Articles found by citation matching

7

An overall summary of the study selection process is presented in Table 4.

Total Number of
Publications
(PubMed)

88
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Table 4
Summary of Study Selection Method
Summary of Study Selection Method

Number of Studies

Selected

15

Duplicate

28

Not Relevant

39

No Abstract Available

2

Not Based on Clinical Trial

4

A flowchart with details of the selection process is depicted in the Figure 3.

Figure 3
Flowchart for the Study Selection Process
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Once the 15 studies were selected for the final evaluation, each study was reviewed for
the primary outcome and secondary outcomes specified in the methods section. The results were
summarized on an Excel spreadsheet and are presented on the Appendix at the end of the thesis.
Out of 15 articles selected, only three articles showed any evidence of potential effects of
hydroxychloroquine, and 12 of the articles indicated the primary outcome as no clinical
improvement confirming lack of efficacy of hydroxychloroquine in COVID-19 patients when
used as treatment. The summary of the primary outcome is presented in Table 5 and Table 6. For
the evaluation of secondary outcome, all 15 articles were reviewed for signs of adverse reactions
caused by hydroxychloroquine in COVID-19 patients. Out of 15 articles, 10 articles did not
indicate any evidence of adverse reactions caused by hydroxychloroquine in COVID-19 patients.
The remaining five articles indicated some evidence of adverse reactions in which some are
specifically addressing cardiac failure. The results of the secondary outcome are presented in
Table 7 and Table 8.

Table 5
Summary of Studies Indicating Evidence of Primary Outcome
Citation

Title of the Selected Articles
Type of Study
Primary Outcome
Assessment of COVID-19
Treatment containing both
Hydroxychloroquine and
Azithromycin: A natural clinical
Reduced signs and
Abbas et al., 2021
trial
Clinical Trial
symptoms significantly
Safety and efficacy of favipiravir
versus hydroxychloroquine in
Favipiravir could be
management of COVID-19: A
Randomized
used as an alternative
Dabbous et al., 2021 randomised controlled trial
Controlled Trial for hydroxychloroquine
Lopinavir-ritonavir and
hydroxychloroquine for critically ill
Randomized,
Worsened outcome
patients with COVID-19: REMAP- Controlled Clinical
compared to no
Arabi et al., 2021
CAP randomized controlled trial
Trial
antiviral therapy
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Table 6
Summary of Studies Indicating No Evidence of Primary Outcome

Citation

Title of the Selected Articles

Recovery
Collaborative
Group, 2020

Effect of Hydroxychloroquine in Hospitalized Patients with
COVID-19
A Cluster-Randomized Trial of Hydroxychloroquine for
Mitja et al., 2021 Prevention of COVID-19
WHO Solidarity
Trial Consortium Repurposed Antiviral Drugs for COVID-19 - Interim WHO
et al., 2021
Solidarity Trial Results
Skipper et al.,
2020

Hydroxychloroquine in Nonhospitalized Adults With Early
COVID-19 : A Randomized Trial

Azithromycin in addition to standard of care versus standard
of care alone in the treatment of patients admitted to the
Furtado et al.,
hospital with severe COVID-19 in Brazil (COALITION II):
2020
a randomised clinical trial
A multicenter, randomized, open-label, controlled trial to
evaluate the efficacy and tolerability of hydroxychloroquine
and a retrospective study in adult patients with mild to
Chen et al., 2020 moderate coronavirus disease 2019 (COVID-19)

Type of Study

Primary
Outcome

Randomized
No Clinical
Controlled Trial
Improvement
Cluster-Randomized No Clinical
Trial
Improvement
Randomized
Controlled Trial

No Clinical
Improvement

Randomized
Controlled Trial

No Clinical
Improvement

Randomized
Controlled Trial

No Clinical
Improvement

Randomized
Controlled Trial

No Clinical
Improvement

Efficacy and Safety of Hydroxychloroquine vs Placebo for
Randomized, double
Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care
blind, PlaceboNo Clinical
Abella et al., 2021 Workers: A Randomized Clinical Trial
Controlled Trial
Improvement
Schwartz et al.,
2021

Assessing the efficacy and safety of hydroxychloroquine as
outpatient treatment of COVID-19: a randomized controlled
trial

Effect of Early Treatment with Hydroxychloroquine or
Lopinavir and Ritonavir on Risk of Hospitalization Among
Patients With COVID-19: The TOGETHER Randomized
Reis et al., 2021 Clinical Trial
Phase 2 randomized study on chloroquine,
hydroxychloroquine or ivermectin in hospitalized patients
Galan et al., 2021 with severe manifestations of SARS-CoV-2 infection

Self et al., 2020
Lyngbakken et
al., 2020

Randomized
Controlled Trial

Randomized Clinical
Trial
Randomized, double
blinded, Phase 2
Trial
Randomized,
Effect of Hydroxychloroquine on Clinical Status at 14 Days
Blinded, Placeboin Hospitalized Patients With COVID-19: A Randomized
Controlled, MultiClinical Trial
center Trial
A pragmatic randomized controlled trial reports lack of
Pragmatic,
efficacy of hydroxychloroquine on coronavirus disease 2019
Randomized,
viral kinetics
Controlld Trial

No Clinical
Improvement

No Clinical
Improvement
No Clinical
Improvement

No Clinical
Improvement
No Clinical
Improvement
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Table 7
Summary of Studies Indicating No Evidence of Secondary Outcome

Citation

Title of the Selected Articles

WHO Solidarity
Trial Consortium et Repurposed Antiviral Drugs for COVID-19 al., 2021
Interim WHO Solidarity Trial Results
Hydroxychloroquine in Nonhospitalized Adults
Skipper et al., 2020 With Early COVID-19 : A Randomized Trial
Azithromycin in addition to standard of care versus
standard of care alone in the treatment of patients
admitted to the hospital with severe COVID-19 in
Furtado et al., 2020 Brazil (COALITION II): a randomised clinical trial
A multicenter, randomized, open-label, controlled
trial to evaluate the efficacy and tolerability of
hydroxychloroquine and a retrospective study in
adult patients with mild to moderate coronavirus
Chen et at., 2020
disease 2019 (COVID-19)
Efficacy and Safety of Hydroxychloroquine vs
Placebo for Pre-exposure SARS-CoV-2
Prophylaxis Among Health Care Workers: A
Abella et al., 2021 Randomized Clinical Trial
Assessing the efficacy and safety of
Schwartz et al.,
hydroxychloroquine as outpatient treatment of
2021
COVID-19: a randomized controlled trial
Effect of Early Treatment with
Hydroxychloroquine or Lopinavir and Ritonavir on
Risk of Hospitalization Among Patients With
COVID-19: The TOGETHER Randomized Clinical
Reis et al., 2021
Trial
Phase 2 randomized study on chloroquine,
hydroxychloroquine or ivermectin in hospitalized
patients with severe manifestations of SARS-CoVGalan et al., 2021 2 infection

Type of
Study

Secondary Outcome

No evidence of adverse
Randomized
reactions mentioned in
Controlled Trial
the article
No evidence of adverse
Randomized
reactions mentioned in
Controlled Trial
the article
No evidence of adverse
Randomized
reactions mentioned in
Controlled Trial
the article

No evidence of adverse
Randomized
reactions mentioned in
Controlled Trial
the article
Randomized,
double blind, No evidence of adverse
Placeboreactions mentioned in
Controlled Trial
the article
No evidence of adverse
Randomized
reactions mentioned in
Controlled Trial
the article

Randomized
Clinical Trial

Self et al., 2020

Randomized,
double blinded,
Phase 2 Trial
Randomized,
Blinded,
PlaceboEffect of Hydroxychloroquine on Clinical Status at
Controlled,
14 Days in Hospitalized Patients With COVID-19:
Multi-center
A Randomized Clinical Trial
Trial

Lyngbakken et al.,
2020

A pragmatic randomized controlled trial reports
lack of efficacy of hydroxychloroquine on
coronavirus disease 2019 viral kinetics

No evidence of adverse
reactions mentioned in
the article
No evidence of adverse
reactions mentioned in
the article

No evidence of adverse
reactions mentioned in
the article

Pragmatic,
No evidence of adverse
Randomized, reactions mentioned in
Controlld Trial
the article
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Table 8
Summary of Studies Indicting Evidence of Secondary Outcome
Citation
Recovery
Collaborative
Group, 2020

Mitja et al., 2021

Abbas et al., 2021

Dabbous et al.,
2021

Arabi et al., 2021

Title of the Selected Articles

Type of Study Secondary Outcome
Invasive Mechanical
Randomized
Ventilation, Cardiac
Controlled Trial
Death
ClusterHigher Adverse
Randomized reactions, No Serious
Trial
Adverse reaction

Effect of Hydroxychloroquine in
Hospitalized Patients with COVID-19
A Cluster-Randomized Trial of
Hydroxychloroquine for Prevention of
COVID-19
Assessment of COVID-19 Treatment
containing both Hydroxychloroquine
and Azithromycin: A natural clinical
Side effects related to
trial
Clinical Trial
heart rythum
Safety and efficacy of favipiravir versus
hydroxychloroquine in management of
COVID-19: A randomised controlled
Randomized
Acute Myocarditis,
trial
Controlled Trial Acute heart failure
Lopinavir-ritonavir and
hydroxychloroquine for critically ill
Randomized,
patients with COVID-19: REMAP-CAP
Controlled
Evidence of Mild
randomized controlled trial
Clinical Trial
Adverse Events

As a result of the literature review done on the efficacy of hydroxychloroquine in
COVID-19 patients, 80% of the articles indicated no evidence of clinical improvement, and only
20% articles indicated effects of hydroxychloroquine in patients with COVID-19. For the
secondary outcome of signs of adverse reactions, 66.7% of the articles indicated no evidence of
adverse reactions, and 33.3% articles indicated signs of adverse reactions. The summary of the
results is presented in Table 9.
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Table 9
Summary of Results in Percent

Summary of Results

% of Articles

Evidence of Primary Outcome (Clinical Improvement)

20

No Evidence of Primary Outcome (Clinical Improvement)

80

Evidence of Secondary Outcome (Adverse Reactions)

33.3

No Evidence of Secondary Outcome (Adverse Reaction)

66.7

As it is presented in Table 9, majority of the articles did not indicate any evidence of
efficacy of hydroxychloroquine in COVID-19 patients. As for the secondary outcome of signs of
adverse reactions, majority of the selected articles did not indicate any evidence of adverse
reactions. Because this is a review of literature, there were not enough conclusive evidence to
state that there is no efficacy for hydroxychloroquine or there are no adverse reactions caused by
hydroxychloroquine in patients with COVID-19. These results are only based on the articles that
were selected for this particular research. The results are discussed in detail in the discussion
section.
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Discussion
For the systematic review of literature to evaluate the efficacy of hydroxychloroquine in
COVID-19 patients, 15 studies were selected for the final review. All the selected studies for the
literature review were based on clinical trials or randomized controlled clinical trials. Out of
fifteen selected studies, the primary outcome for twelve studies indicated no clinical
improvement caused by hydroxychloroquine in COVID-19 patients (refer to Table 6). One
specific study indicated reduction of signs and symptoms significantly (Abbas et al., 2021), and
another study indicated worsened outcome compared to no antiviral therapy (Arabi et al., 2021).
One study indicated favipiravir as a possible alternative for hydroxychloroquine for the treatment
of COVID-19 (Dabbous et al., 2021). Based on the literature review of the 15 articles selected
for this research, it is concluded that there was no clinical improvement using
hydroxychloroquine in COVID-19 patients. The lack of efficacy of hydroxychloroquine for the
treatment of COVID-19 is evident from the results of the literature review. The conclusion
agrees with the fact that the FDA revoked the emergency use authorization for the use of
hydroxychloroquine in COVID-19 patients due to lack of improvement on the symptoms.
For the evaluation of the secondary outcome, all 15 studies were reviewed for any
evidence of adverse reactions reported in COVID-19 patients as a result of using
hydroxychloroquine as a treatment. Ten studies did not mention any evidence of adverse
reactions (refer to Table 7), and five studies indicated evidence of adverse reactions mostly
related to heart failure. The article titled as “Effect of Hydroxychloroquine in Hospitalized
Patients with COVID-19” indicated invasive mechanical ventilation and cardiac death as the
adverse reactions caused by hydroxychloroquine (Recovery Collaborative Group, 2020).
According to Abbas et al. (2021), the adverse reactions were associated with heart rhythm. Acute
myocarditis and acute heart failure are also recorded as adverse reactions based on article titled
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as “Safety and Efficacy of Favipiravir Versus Hydroxychloroquine in Management of COVID19: A Randomised Controlled Trial” (Dabbous et al., 2021). There were two studies mentioning
evidence of adverse events in general without specific details, caused by hydroxychloroquine in
COVID-19 patients (Mitja et al., 2021; Arabi et al., 2021). The results from the literature review
do not have enough evidence for any strong conclusion regarding adverse reactions of
hydroxychloroquine in COVID-19 patients. Because the selected studies for this research do not
indicate any conclusive evidence of adverse reactions caused by hydroxychloroquine in COVID19 patients, the subject is discussed in detail with more evidence from recently published studies.
The most common reported adverse reaction of hydroxychloroquine in COVID-19
patients is prolonged QT interval which predisposes to ventricular tachycardia (Pareek et al.,
2020). QT interval is measured on electrocardiogram which is used to assess some of the
electrical properties of the heart. The primary concern with short term, high dose 4aminoquinoline regimen is cardiovascular toxicity (Recovery Collaborative Group, 2020).
Corona virus disease (COVID-19) is a pro-arrhythmogenic state created by direct viral
myocardial damage, hypoxia, hypotension, enhanced inflammatory status, electrolyte
abnormalities, concomitant QT-prolongation medications, and underlying cardiovascular
diseases, with the risk of being higher in patients with severe COVID-19 (Pareek et al., 2020).
Combined use of hydroxychloroquine and azithromycin was also adopted globally to
treat COVID-19 patients. Studies indicate that this combination also results in significant QT
prolongation in approximately one in four hospitalized patients. The degree of QT prolongation
is severe, exceeding 500 milliseconds in 14% of patients and resulting in a case of Torsades de
Pointes (Maraj et al., 2020). Torsades de Pointes is considered as one of several types of lifethreatening heart rhythm disturbances. Based on these studies, it is evident that
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hydroxychloroquine and the combination of hydroxychloroquine with azithromycin could trigger
cardiac failures in patients with COVID-19.
Studies indicated that COVID-19 patients could be more susceptible to adverse reactions
caused by hydroxychloroquine because of the compromised functions of the vital organs caused
by COVID-19 infection. Since hydroxychloroquine is cleared by the kidney and the liver,
patients who are highly sick particularly ones with impaired renal or hepatic functions, are at
increased risk of experiencing serious adverse reactions (Younis et al., 2020). Drug-drug
interactions are also a major cause of adverse reactions associated with hydroxychloroquine
(Younis et al., 2020). Additionally, there were several other non-life-threatening side effects like
diarrhea, non-specific abdominal pain, dyspepsia, bloating, nausea, vomiting, headache, skin
rash, insomnia, dizziness, fatigue, and blurred vision, etc, observed in COVID-19 patients as a
result of the use of hydroxychloroquine.
Based on the adverse reactions listed on the package insert and recent studies published,
the suggested warning at the time of prescription that could be beneficial to the patients are
mainly for retinal toxicity and cardiotoxicity. Recent studies in COVID-19 patients indicated that
hydroxychloroquine could cause blurred vision in some patients. Even though retinal toxicity is
caused by prolonged use of hydroxychloroquine, doctors should warn about this and explain the
seriousness of this side effect at the time of prescription so that patients could be aware of it and
could consult with the ophthalmologist for regular monitoring. Ophthalmologists,
rheumatologists, and general practitioners should be aware of the best practices in safe
prescribing of hydroxychloroquine and any consensus criteria to ensure those who require
screening for hydroxychloroquine retinopathy are appropriately referred (Yusuf, 2017).
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Recommendation for Future Research
Based on the evaluation of the articles with the adverse drug reactions associated with
hydroxychloroquine, it can be concluded that additional research was mostly done in the area of
cardiac ADRs and retinal toxicity. There was not much evidence collected in terms of additional
research around allergic reactions caused by hydroxychloroquine. With the COVID-19 situation,
a lot of research has been done and is in process around QT prolongation and cardiac arrhythmia.
Several studies have been conducted to investigate cardiotoxicity associated with
hydroxychloroquine usage in both non-Covid and Covid-infected patients. A total of 3,237
studies are currently registered at the U.S. National Institute of Health’s National Library of
Medicine portal from 114 countries, of which 793 are investigating various treatment options in
Copvid-19 (Raza et al., 2021). Among these, a total of 68 studies refer to hydroxychloroquine
usage in COVID-19 (Raza et al., 2021). Based on the research that was used to write this thesis,
it is recommended that additional research about cardiac adverse reactions and allergic reactions
associated with hydroxychloroquine use will also be beneficial to patients at the time of
prescription.
Limitation of the Study
The primary limitation of this thesis was the limited number of databases used for the
keyword search as the studies were only included from PubMed. Another limitation was the type
of study chosen to include in the literature review as it only included clinical trials and
randomized clinical trials.
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Conclusion
The global pandemic known as COVID-19 brought hydroxychloroquine to the forefront
of the medical world and to the research community as a potential treatment for COVID-19, but
without the support of clinical data. Even though there was not much research done on this
medicine nor any major regulatory updates done since the approval, a lot of research studies have
been done already or are in process due to the use of this medicine as potential treatment in the
early stages of the pandemic. The conclusion of this research study based on the literature review
and analysis is that there is no evidence of clinical improvement caused by hydroxychloroquine
in COVID-19 patients. Based on this study, there are no conclusive evidence for any signs of
adverse reactions in patients with COVID-19 as a result of using hydroxychloroquine as
treatment. The conclusion of this research confirms the FDA’s decision to revoke the emergency
use authorization as there is lack of evidence for clinical improvement. Additional research is
highly recommended in the areas of cardiotoxicity and cutaneous adverse reactions in order to
minimize the consequences of severe adverse reactions caused by hydroxychloroquine in
patients.
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